HB3454 is a broad update to Illinois laws governing epinephrine access and emergency response, with related changes to school asthma medication rules, opioid antagonist use, and insurance coverage. The bill replaces older references to “epinephrine auto-injectors” with the broader term “FDA approved epinephrine delivery device or product,” and defines that term to include both auto-injectors and FDA-approved pre-filled syringes that deliver a pre-measured dose of epinephrine. It also renames the underlying law to the “FDA Approved Epinephrine Delivery Device or Product Act” and updates the Annie LeGere Law references across multiple statutes.
A major part of the bill expands and modernizes emergency-medication authority in schools, recreation camps, after-school care programs, and other authorized entities. It preserves and clarifies when students may self-carry and self-administer epinephrine or asthma medication, when schools may stock undesignated epinephrine, asthma medication, oxygen tanks, and opioid antagonists, and when trained personnel may administer them in good faith during anaphylaxis, respiratory distress, or opioid overdose. The bill also adds or updates training, reporting, notice, and recordkeeping requirements for schools and other covered entities, including annual training, EMS activation, parent notification, and reporting to the State Board of Education.
HB3454 also amends the Illinois Insurance Code to require coverage for medically necessary FDA-approved epinephrine delivery devices or products for persons 18 years of age or under, and caps insured cost-sharing for a twin-pack at no more than $60, subject to high-deductible health plan rules. In addition, it updates the Medical Practice Act and the Food, Drug and Cosmetic Act to align terminology and protect prescribers and dispensers acting under the epinephrine laws. The bill makes conforming changes across the School Code, Illinois State Police Act, Illinois Police Training Act, Emergency Asthma Inhalers and Allergy Treatment for Children Act, and Home Health and Hospice Drug Dispensation and Administration Act.
The overall sentiment reflected in the bill text is strongly supportive of emergency preparedness and access to life-saving medication, with an emphasis on expanding practical options and reducing liability concerns for schools, law enforcement, and other entities. Because no committee transcripts or recorded votes were provided, there is no documented floor or committee debate to indicate opposition or amendments beyond the statutory revisions themselves. The bill’s structure suggests a technical and policy-driven update rather than a controversial overhaul, focused on modernizing terminology and broadening access to epinephrine and related emergency treatments.
The main points of contention likely center on liability protections, training burdens, reporting requirements, and the scope of who may administer medication in emergencies. The bill gives broad immunity except for willful and wanton conduct, which may be important to schools, camps, and law enforcement but could raise concerns for some stakeholders about accountability. Another possible issue is the expansion from auto-injectors to a broader class of FDA-approved delivery devices and products, which may be welcomed as medically current but could require implementation changes in procurement, training, and policy development.
HB3454 would revise multiple Illinois statutes to replace the narrower term “epinephrine auto-injector” with “FDA approved epinephrine delivery device or product,” thereby broadening the legal framework to cover additional FDA-approved epinephrine formats. It would update school-health, law-enforcement, insurance, medical-practice, and emergency-medication provisions, while also preserving and extending authority for self-administration, stock supplies, standing orders, training, and immunity protections. Affected parties include schools, school nurses, trained personnel, law enforcement agencies, recreation camps, after-school programs, health care practitioners, insurers, and authorized entities that stock and use epinephrine.
The bill appears generally favorable and public-safety oriented, with a clear emphasis on improving access to emergency treatment for anaphylaxis and related conditions. The text reflects a consensus-style update to existing law, and no committee testimony or vote record was provided showing organized opposition. The policy direction is supportive of schools and other entities being able to respond quickly to allergic emergencies, opioid overdoses, and respiratory distress.
The most likely areas of disagreement are the bill’s liability shields, mandatory training and reporting obligations, and the expansion of who may carry and administer emergency medication. Schools and other covered entities may support the protections and flexibility, while some stakeholders could be concerned about compliance costs, administrative burden, or the breadth of immunity from civil or professional liability. The switch to broader FDA-approved epinephrine delivery devices may also prompt questions about implementation, procurement, and whether existing policies and training materials will need substantial revision.